Darren Kelly, Certa Therapeutics CEO
February 7, 2023 10:59 AM EST
R&D

Aus­tralian biotech touts a pos­i­tive mid-stage da­ta read­out — with old Shire drug

Paul Schloesser

Associate Editor

A qui­et biotech is re­port­ing some pos­i­tive da­ta in a rare fi­brot­ic dis­ease.
Cer­ta Ther­a­peu­tics — based in Mel­bourne, Aus­tralia — re­port­ed Mon­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

Is there room for MASH drugs in a GLP-1 world?

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

No­vo adds to We­govy’s car­dio strength with hos­pi­tal ad­mis­sions analy­sis

Cin­Rx touts pos­i­tive ear­ly-stage da­ta from two obe­si­ty can­di­dates

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times